Abstract
This is a 78-week (approximately a year and a half) open-label extension study of Beremagene Geperpavec (B-VEC), for participants aged 6 months and older, who have been diagnosed with Dystrophic Epidermolysis Bullosa (DEB). Participants will be dosed weekly with the topical B-VEC therapy. The primary endpoint will be to assess long term safety and tolerability of the topical gene therapy. The study is for those who participated in Phase III study, as well as, new participants who were unable to participate in the Phase III study, who meet all enrollment criteria.
